John Stults, Genentech Senior Protein Scientist, Joins Stealth Startup Biospect

Sep 09, 2002

Premium

What does John Stults know? He’s not saying much, but confirms that he has ended a 15-year career at Genentech to jump to a proteomics startup.

Stults, the 44-year-old former senior scientist for protein chemistry at Genentech, told ProteoMonitor last week that he has joined Biospect, a San Francisco firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

This Week in PLOS

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

Isolation Worries

An opinion piece at Bloomberg discusses China's stance on genomic research.

Shaken Identity

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Free-Ish

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

Featured White Papers

A Mammalian System for Antibody/Protein Library Screening

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Main menu